PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Dunger, D.B.* ; Bruggraber, S.F.A.* ; Mander, A.P.* ; Marcovecchio, M.L.* ; Tree, T.* ; Chmura, P.J.* ; Knip, M.* ; Schulte, A.M.* ; Mathieu, C.* ; INNODIA consortium (Ziegler, A.-G.) ; INNODIA consortium (Achenbach, P.) ; INNODIA consortium (Rodriguez-Calvo, T.)

INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes.

Trials 23:414 (2022)
Publ. Version/Full Text DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
BACKGROUND: The INNODIA consortium has established a pan-European infrastructure using validated centres to prospectively evaluate clinical data from individuals with newly diagnosed type 1 diabetes combined with centralised collection of clinical samples to determine rates of decline in beta-cell function and identify novel biomarkers, which could be used for future stratification of phase 2 clinical trials. METHODS: In this context, we have developed a Master Protocol, based on the "backbone" of the INNODIA natural history study, which we believe could improve the delivery of phase 2 studies exploring the use of single or combinations of Investigational Medicinal Products (IMPs), designed to prevent or reverse declines in beta-cell function in individuals with newly diagnosed type 1 diabetes. Although many IMPs have demonstrated potential efficacy in phase 2 studies, few subsequent phase 3 studies have confirmed these benefits. Currently, phase 2 drug development for this indication is limited by poor evaluation of drug dosage and lack of mechanistic data to understand variable responses to the IMPs. Identification of biomarkers which might permit more robust stratification of participants at baseline has been slow. DISCUSSION: The Master Protocol provides (1) standardised assessment of efficacy and safety, (2) comparable collection of mechanistic data, (3) the opportunity to include adaptive designs and the use of shared control groups in the evaluation of combination therapies, and (4) benefits of greater understanding of endpoint variation to ensure more robust sample size calculations and future baseline stratification using existing and novel biomarkers.
Impact Factor
Scopus SNIP
Scopus
Cited By
Altmetric
2.728
0.000
2
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Beta-cell Function ; C-peptide ; Master Protocol ; Phase 2 ; Prevention ; Trials ; Type 1 Diabetes
Language english
Publication Year 2022
HGF-reported in Year 2022
ISSN (print) / ISBN 1468-6708
e-ISSN 1745-6215
Journal Trials
Quellenangaben Volume: 23, Issue: 1, Pages: , Article Number: 414 Supplement: ,
Publisher BioMed Central
Publishing Place London
Reviewing status Peer reviewed
Institute(s) Institute of Diabetes Research (IDF)
POF-Topic(s) 30201 - Metabolic Health
Research field(s) Helmholtz Diabetes Center
PSP Element(s) G-502100-001
G-502190-001
DOI 10.1186/s13063-022-06259-z
PubMed ID 35585600
Erfassungsdatum 2023-02-23
[➜Report correction]